Literature DB >> 20391295

Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver.

Giovanni Targher1, Giacomo Zoppini, Paolo Moghetti, Chris P Day.   

Abstract

Abdominal obesity represents a public health concern because its prevalence is reaching epidemic proportions worldwide, and it is associated with an increased risk of cardiovascular morbidity and mortality and other pathological conditions. A large body of evidence suggests that abdominal obesity is associated with a prothrombotic tendency, which may, at least in part, contribute to the increased risk of atherothrombosis in these individuals. This review briefly summarizes the evidence of direct and indirect effects of the accumulation of excess lipid in visceral adipose tissue on coagulation and fibrinolysis. In addition, this article critically appraises the rapidly expanding body of experimental and clinical data that support a potential direct contribution for the accumulation of excess lipid in the liver (i.e., nonalcoholic fatty liver disease, a very frequent pathological condition in subjects with abdominal obesity) in the pathogenesis of the obesity-induced disorders of coagulation and fibrinolysis.

Entities:  

Mesh:

Year:  2010        PMID: 20391295     DOI: 10.1055/s-0030-1248723

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  17 in total

Review 1.  Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.

Authors:  Enzo Bonora; Giovanni Targher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-08       Impact factor: 46.802

2.  Effect of omega-3 fatty acids on haemostatic functions in urocortin-treated obese rats.

Authors:  Ahmed A El-Gendy; Amr M Abbas
Journal:  J Physiol Biochem       Date:  2014-07-26       Impact factor: 4.158

Review 3.  Arterial thrombus formation in cardiovascular disease.

Authors:  Giuseppe Lippi; Massimo Franchini; Giovanni Targher
Journal:  Nat Rev Cardiol       Date:  2011-07-05       Impact factor: 32.419

Review 4.  Obesity and Altered Aspirin Pharmacology.

Authors:  Nicholas B Norgard
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

5.  Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.

Authors:  Anna K Kopec; Nikita Joshi; Keara L Towery; Karen M Kassel; Bradley P Sullivan; Matthew J Flick; James P Luyendyk
Journal:  J Pharmacol Exp Ther       Date:  2014-08-19       Impact factor: 4.030

6.  Hepatic CD36 downregulation parallels steatosis improvement in morbidly obese undergoing bariatric surgery.

Authors:  E Pardina; R Ferrer; J Rossell; D Ricart-Jané; K A Méndez-Lara; J A Baena-Fustegueras; A Lecube; J Julve; J Peinado-Onsurbe
Journal:  Int J Obes (Lond)       Date:  2017-05-10       Impact factor: 5.095

7.  Inflammatory and prothrombotic parameters in normotensive non-diabetic obese women: effect of weight loss obtained by gastric banding.

Authors:  Massimo Cugno; Roberto Castelli; Daniela Mari; Enrico Mozzi; Marco Antonio Zappa; Massimo Boscolo-Anzoletti; Giancarlo Roviaro; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2011-01-20       Impact factor: 3.397

8.  CUSHING'S SYNDROME, A RISK FACTOR FOR VENOUS THROMBOEMBOLISM IS A CANDIDATE FOR GUIDELINES.

Authors:  G Koraćević; M Stojanović; S Petrović; D Simić; D Sakač; M Vlajković; M Stevic; M Kocić; M Đorđević; M Koraćević
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

9.  Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women's interagency HIV study (WIHS).

Authors:  Elizabeth M Kiefer; Qiuhu Shi; Donald R Hoover; Robert Kaplan; Russell Tracy; Michael Augenbraun; Chenglong Liu; Marek Nowicki; Phyllis C Tien; Mardge Cohen; Elizabeth T Golub; Kathryn Anastos
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

10.  Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.

Authors:  Karen M Kassel; Bradley P Sullivan; Wei Cui; Bryan L Copple; James P Luyendyk
Journal:  Am J Pathol       Date:  2012-07-26       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.